Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results

Anika Therapeutics (NASDAQ:ANIK) issued its earnings results on Wednesday. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.34, FiscalAI reports. The business had revenue of $29.61 million during the quarter, compared to analysts’ expectations of $28.14 million. Anika Therapeutics had a negative net margin of 9.64% and a negative return on equity of 6.26%.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Anika reported Q1 revenue of $29.6 million (up 13% YoY), gross margin improved to 64% from 56%, adjusted EBITDA was $4.3 million, the company finished the quarter with $41 million in cash and no debt, and completed a $15 million share repurchase; full-year guidance was maintained.
• Integrity momentum accelerated—U.S. procedures rose 35% YoY, the product surpassed 3,000 cases, larger sizes launched, and new surgeon adoption is growing double-digit month-over-month, supporting TAM expansion beyond the current ~8% augmentation usage.
• Operational transformation is showing early benefits: lean manufacturing, higher throughput, and productivity improvements drove meaningful gross margin improvement and contributed to a >$4 million year-over-year increase in adjusted EBITDA.
• Regulatory progress continues but timing remains uncertain—Hyalofast PMA review is active with a deficiency response expected in the coming months, Cingal’s bioequivalence study is on track, and Cingal, Monovisc, and Hyalofast have EU MDR certifications.
• Revenue and margin are subject to OEM channel and product-mix volatility (Q1 OEM revenue benefited from order timing), SG&A included $4.9 million of one-time severance, and R&D spend rose as the company invests in pipeline programs, creating potential quarter-to-quarter variability.

Anika Therapeutics Trading Down 18.8%

Shares of NASDAQ ANIK opened at $12.39 on Thursday. The firm has a 50 day moving average of $14.27 and a 200 day moving average of $11.28. The firm has a market capitalization of $166.03 million, a price-to-earnings ratio of -16.30 and a beta of 0.28. Anika Therapeutics has a 12-month low of $7.87 and a 12-month high of $16.24.

More Anika Therapeutics News

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Q1 outperformance — Anika reported revenue of $29.61M and GAAP EPS of $0.27, beating consensus on both top- and bottom-line. The beats show near-term commercial strength versus expectations. Press Release / Slides
• Positive Sentiment: Margin and operational progress — Gross margin improved to ~64% (up ~8 pts y/y) and management cites $4M of adjusted EBITDA from operational transformation, supporting future profitability prospects. GlobeNewswire Release
• Neutral Sentiment: FY2026 revenue guidance set to $114.0M–$122.5M — band overlaps Street estimates (~$117.2M) but is wide; management gave revenue guidance while EPS guidance was not clearly specified in initial release. That ambiguity leaves room for differing investor interpretations. MarketBeat Summary
• Neutral Sentiment: Revenue drivers include commercial strength and favorable OEM order timing — positive for near-term growth but suggests potential lumpy/OEM-driven seasonality going forward. GlobeNewswire Release
• Negative Sentiment: Regulatory uncertainty flagged — commentary described “regulatory hurdles” even as momentum exists, creating execution risk for product rollouts or approvals that investors penalize. TipRanks: Regulatory Hurdles
• Negative Sentiment: Company still showing negative net margin and negative ROE; analysts expect FY EPS to remain negative — the beat didn’t eliminate concerns about profitability and longer-term earnings power. MarketBeat Stock Page

Institutional Trading of Anika Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC grew its position in Anika Therapeutics by 4.3% during the fourth quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 1,324 shares during the period. Invesco Ltd. grew its position in Anika Therapeutics by 7.9% during the fourth quarter. Invesco Ltd. now owns 25,272 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,843 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Anika Therapeutics during the fourth quarter valued at approximately $122,000. NewEdge Advisors LLC bought a new stake in Anika Therapeutics during the fourth quarter valued at approximately $139,000. Finally, XTX Topco Ltd increased its stake in shares of Anika Therapeutics by 74.3% in the fourth quarter. XTX Topco Ltd now owns 22,252 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 9,482 shares in the last quarter. 91.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on ANIK shares. Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Barrington Research lifted their target price on shares of Anika Therapeutics from $16.00 to $17.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Anika Therapeutics has an average rating of “Hold” and an average price target of $17.00.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.